Search Results for "sildenafil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for sildenafil. Results 1 to 7 of 7 total matches.
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
of the phosphodiesterase-
5 (PDE5) inhibitor sildenafil for treatment
of Alzheimer’s disease (AD).
PDE5 INHIBITORS ...
A reader asked us to review use of the
phosphodiesterase-5 (PDE5) inhibitor sildenafil for
treatment of Alzheimer's disease (AD).
Shockwave Therapy for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
are generally treated initially with an oral phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil ...
Low-intensity extracorporeal shockwave therapy
similar to that used to fragment kidney stones or
gallstones is a new option for treatment of erectile
dysfunction that is now being advertised extensively
in the US. It has not been approved by the FDA for
treatment of erectile dysfunction.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):190-1 doi:10.58347/tml.2023.1690d | Show Introduction Hide Introduction
Eroxon — An OTC Gel for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
phosphodiesterase
type 5 (PDE5) inhibitors such as avanafil (Stendra),
sildenafil (Viagra, and generics ...
The FDA has authorized over-the-counter (OTC)
sale of a nonmedicated alcohol-based gel (Eroxon –
Futura) for treatment of erectile dysfunction (ED) in
males ≥22 years old. Eroxon is the only FDA-approved
OTC and topical treatment for erectile dysfunction. It
is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2 doi:10.58347/tml.2024.1715c | Show Introduction Hide Introduction
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
Phosphodiesterase-5 (PDE5) Inhibitors6
Sildenafil – generic 20 mg tabs; 10 mg/mL susp 20 mg PO tid $18.905
Revatio ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
-5 (PDE5)
inhibitors such as sildenafil (Viagra, and others) is not
recommended.
PREGNANCY ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
such as sildenafil should not be taken with
isosorbide dinitrate/hydralazine because additive
hypotensive effects ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for HFrEF
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
.
Concurrent use of phosphodiesterase 5 (PDE5)inhibitors such as sildenafil is not recommendedbecause ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 doi:10.58347/tml.2025.1729b | Show Introduction Hide Introduction